The Board of HMS Networks AB (publ) has resolved to exercise authorization to repurchase shares
Based on the authorization granted by the Annual General Meeting on April 23, 2021, the Board of Directors of HMS Networks AB (publ) ("HMS") has resolved to repurchase own shares in the company on Nasdaq Stockholm. Repurchase of the company’s own shares shall be carried out in a repurchase program with the purpose of securing HMS’ obligations to deliver performance shares according to HMS’ Share Saving Plan 2022-2025.
The repurchases may commence on October 25, 2021 and will take place on one or more occasions during the period until the Annual General Meeting 2022. The repurchases will take place on Nasdaq Stockholm in accordance with the Nordic Main Market Rulebook for Issuers of Shares and be administrated by Skandinaviska Enskilda Banken AB (publ), which will take trading decisions independently of HMS with regard to the timing of the repurchase.
Repurchases will be made at a price per share within the registered price interval, which refers to the interval between the highest buying price and the lowest selling price. No more than 81,000 shares may be acquired. Payment of the shares will be settled in cash. Reporting will be made to Nasdaq Stockholm in accordance with applicable rules.
Repurchase of shares may not result in HMS’ holding of own shares, at any time, exceeding 10 percent of the total number of shares in the company. At the time of this press release, the total number of registered shares in the company amounts to 46,818,868 and the total number of shares held by HMS amounts to 157,571 own shares.
For more information, please contact:
Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01
Joakim Nideborn, CFO HMS, +46 (0)35 710 6983
HMS Networks AB (publ) is a market-leading provider of solutions in industrial information and communication technology (Industrial ICT). HMS develops and manufactures products under the Anybus®, Ixxat®, Ewon® and Intesis® brands. Development takes place at the headquarter in Halmstad and also in Ravensburg, Nivelles, Igualada, Wetzlar, Buchen, Delft and Bilbao. Local sales and support are handled by branch offices in Germany, USA, Japan, China, Singapore, Italy, France, Spain, the Netherlands, India, UK, Sweden, South Korea and UAE, as well as through a worldwide network of distributors and partners. HMS employs over 700 people and reported sales of SEK 1,467 million in 2020. HMS is listed on the NASDAQ OMX in Stockholm, category Mid Cap, Information Technology.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES30.11.2021 09:30:00 CET | Press release
Bid date, 2021-11-30Auction date2021-11-30Settlement date2021-12-01Maturity Date2021-12-08Nominal amount570 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to email@example.comThe lowest accepted bid volume1 million SEKThe highest accepted bid volume570 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term1140 billion SEKExpected excess liquidity at full allotment570 billion SEK Stockholm, 2021-11-30
Stratio raises $12M Series A to Scale AI-based Predictive Fleet Maintenance Platform using Real-time Augmented Intelligence30.11.2021 09:02:00 CET | Press release
Investment led by Forestay with participation from existing investor Crane Venture Partners to be used to further accelerate global expansion, increase R&D, boost product development, and double headcount by the end of 2022 LISBON, Portugal and LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Stratio, the world’s leading real-time predictive fleet maintenance platform, today announced a $12M Series A funding round to further accelerate its growth. The investment, led by Forestay Capital, the Deep Tech and SaaS Venture Capital arm of Waypoint Capital, with participation from existing investor Crane Venture Partners, will be used to further accelerate the company’s global expansion, increase its R&D, speed up overall time-to-market, and double its headcount by the end of 2022. Stratio already has its technology deployed in 5 of the top 10 transportation companies in the world and has enabled transportation for 1.3 billion people so far. The company’s Annual Recurring Revenue (ARR) has grown 270
Not intended for U.S. Media – Solvay announces results of its tender offer to purchase bonds for cash30.11.2021 08:32:08 CET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA OR TO ANY U.S. PERSON OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. Solvay SA continues its deleveraging through the early redemption of bonds due in 2022 Brussels, 30 November 2021 --- Solvay SA (the “Issuer”) today successfully closed the tender offer on its outstanding EUR 750 million 1.625% bonds due 2022, by acquiring €372.5 million of senior debt, marking another step in the strong deleveraging that commenced in 2019. As part of its G.R.O.W. strategy, Solvay has prioritised cash generation and, since January 2019, has generated €2.3 billion operationally, both from improving
Sampo plc’s share buybacks 29/11/202130.11.2021 08:30:00 CET | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 30/11/2021 at 08:30 am Sampo plc’s share buybacks 29/11/2021 On 29/11/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)33,86443.34AQEU34,08143.27CEUX4,67243.25TQEX109,28243.26XHELTOTAL181,89943.28 *rounded to two decimals On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 5,631,827 Sampo A shares representing 1.01 per cent of the total number of shares in Sampo plc. Detai
Aino Health AB (publ): Världsledande tillverkare väljer Aino Healths SaaS-lösning HealthManager30.11.2021 08:30:00 CET | Pressemelding
Stockholm 30 November, 2021. Ett världsledande tillverkningsföretag och global marknadsledare inom aggregat-, mineralbearbetnings- och metallraffineringsindustrin har valt att utöka användningen av Aino Healths SaaS-lösning HealthManager. Avtalet innehåller totalt 2 400 licenser, varav 1 300 är nya licenser. "Vi är mycket glada och stolta över att fortsätta och utöka en nyckelaktör inom tillverkningsindustrin som kund. Vi ser fram emot att tillsammans öka personalens välbefinnande och engagemang", säger Jyrki Eklund, VD Aino Health. HealthManager är Ainos egen SaaS-lösning som stödjer chefer med interna hälsorelaterade processer och frånvarohantering. Det erbjuder också rapporterings- och analysverktyg för att följa viktiga mätvärden relaterade till företagets hälsohantering. Målet med lösningen är att digitalisera arbetsförmågasprocesser och öka medarbetarnas engagemang. Om Aino Health (publ) Aino Health är den ledande leverantören av Software as a Service-lösningar inom Corporate Hea
Aino Health AB (publ): World leading manufacturer chooses Aino Health's SaaS-solution HealthManager30.11.2021 08:30:00 CET | Press release
Stockholm 30 November, 2021. A world leading manufacturing company and global market leader for sustainable technologies in the aggregates, minerals processing and metals refining industries, has chosen to extend the usage of Aino Health’s SaaS-solution HealthManager. The agreement contains a total of 2 400 licenses, out of which 1 300 are new licenses. ”We are very happy and proud to continue and extend a key player in the manufacturing industry as a customer. We look forward to together increase their personnel’s’ wellbeing and engagement”, says Jyrki Eklund, CEO Aino Health. HealthManager is Ainos own SaaS solution that supports managers with internal health-related processes and absence management. It also offers reporting and analytic tools to follow key metrics related to corporate health management. The goal of the solution is to digitalize working ability processes and to increase employee engagement. About Aino Health (publ) Aino Health is the leading supplier of Software as a
PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments30.11.2021 08:00:00 CET | Press release
Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today an extension of their current collaboration. The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen concept, which has been invented by Immunicum, could benefit from PCI Biotech’s antigen delivery technologies based on Photochemical Internalisation. Following the encouraging results of the first set of in vitro experiments, during which the delivery protocol of the combination treatment has been optimized, the c